% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • wilderguide wilderguide Jun 25, 2013 6:06 PM Flag

    Dr. Shaw on Crizotinib Versus Chemotherapy in ALK-Positive NSCLC

    Onlive today 6/25/13....
    Getting the clinical mojo to stage with Crizotinib is the best thing that can happen to ganetespib...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This may well may well have been the driving force behind all of SNTA's Insider Buying.

      Insider buying started on June 4th and has continued , I believe that article came out on June 1st which was a Sat,

      • 1 Reply to lilgodfther
      • $$$$
        "This may well may well have been the driving force behind all of SNTA's Insider Buying"

        Perhaps...but I see another "sleeper" in NCT01551693. It is a P2 trial of Ganetespib in advanced melanoma. Trial enrollment is only projected at 50, with a data collection date of June 2013. Recently published findings from Moffitt Cancer Center in Florida suggest strong rationale for HSP90i in combination with Zelboraf. They are working with XL-888, the HSP90i from EXEL. XL-888 is thought to overcome BRAF inhibitor resistance. It wouldn't surprise me that G has the same capacity. The Moffitt study is still in P1...

        If the P2 melanoma NCT01551693 reports a reasonable OS signal of G monotherapy, I would expect to soon see a P3 trial both G monotherapy and (quite possibly) in combination with Z (vemurafinib) Makes sense to capitalize on existing published research, and might also account for the recent lively run-up of insider buying.

0.3430.000(0.00%)Jul 22 3:59 PMEDT